Clinical Trial Update: Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating ipilimumab combined with nivolumab for recurrent, high-risk resectable melanoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: University of Utah | Conditions: Melanoma | Phase 2 | Status: RECRUITING